在髓瘤中抑制PIKfyve会破坏自和溶酶体,增加MHC表达和胆固醇代谢
Cecilia Bonolo De Campos1, Ruijuan He1, Tessa Josephine Pelino2
1University Health Network - Princess Margaret Cancer Center, Toronto, Ontario, Canada.
Blood
|November 5, 2025
概括
针对PIKfyve (酸-3-酸5激酶) 的新型小分子抑制剂显示出强大的抗多发性骨髓瘤 (MM) 活性. 这种方法也表明了对其他癌症的潜力,并提供了对抗药性机制的见解.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 酸-3-酸5激酶 (PIKfyve) 被确定为多发性骨髓瘤 (MM) 的脆弱标.
- PIKfyve调节了必不可少的细胞过程,如 lysosomal 功能和自,对于MM生存和免疫球蛋白合成至关重要.
研究的目的:
- 开发和描述PIKfyve的新型小分子抑制剂.
- 评估PIKfyve抑制在多发性骨髓瘤和其他癌症中的疗效和机制.
主要方法:
- 开发和描述PIK001和同类药物,选择性PIK抑制剂.
- 实验室反MM活性评估,包括与现有药物的协同作用和耐药模型中的疗效.
- 耐药细胞系的多原子分析以确定耐药机制 (例如,PIKFYVEN1939K突变).
主要成果:
- PIK001显示出强大的抗MM活性和与venetoclax和selinexor的协同效应.
- 在耐莱利多米德的MM模型中,有效性被保留.
- 抑制PIKfyve影响了胆固醇代谢,上调了MHC I类表达,并在其他癌症 (AML,黑色素瘤,脏) 中表现出细胞毒性.
结论:
- 抑制PIKfyve是MM和其他血液恶性瘤的验证治疗标.
- PIK001和类似的药物为进一步开发提供了一个有希望的临床前基础.
- 进一步的研究是必要的,对胆固醇代谢和瘤免疫影响的PIKfyve抑制.
相关概念视频
Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
Autophagy
5.6K
Autophagy is a self-digesting process by which a cell protects itself from threats both within and outside the cell, ranging from abnormal proteins to invading bacteria. In this process, obsolete components of the cell and invading microbes are degraded by hydrolytic enzymes active in an acidic environment of the lysosomal lumen.
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
5.6K
The Intrinsic Apoptotic Pathway
8.2K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.2K
Delivery Pathways to the Lysosome
8.7K
Eukaryotic cells use different mechanisms to eliminate toxic waste obsolete and worn-out substances. Lysosomes play a pivotal role in this, and hence, these substances are carried to the lysosome from other parts of the cell and extracellular space through different pathways. The most elaborately studied pathways to the lysosome are the endocytic pathways.
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...
8.7K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K


